Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maryka Quik

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Molecular Pharmacology|August 25, 2010
α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's diseaseXiomara A Perez, Tanuja Bordia, J Michael McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 8, 2012
Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbensXiomara A Perez, Jason Ly, J Michael McIntosh, et al.
Molecular Pharmacology|April 6, 2007
Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatumTanuja Bordia, Sharon R Grady, J Michael McIntosh, et al.
Channels (Austin, Tex.)|October 14, 2008
Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applicationsBaldomero M Olivera, Maryka Quik, Michelle Vincler, et al.
Pharmacology Research & Perspectives|February 19, 2015
Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawalXiomara A Perez, Taline V Khroyan, J Michael McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2012
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatumTanuja Bordia, Maya Hrachova, Matthew Chin, et al.
Neurobiology of Disease|February 28, 2016
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasTanuja Bordia, Xiomara A Perez, Jaime Heiss, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2002
Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damageJennifer M Kulak, John L Musachio, J Michael McIntosh, et al.
Neuropharmacology|January 15, 2011
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian ratsLuping Z Huang, Carla Campos, Jason Ly, et al.
Journal of Neurochemistry|March 3, 2009
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeysLuping Z Huang, Neeraja Parameswaran, Tanuja Bordia, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Molecular Pharmacology|August 25, 2010
α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's diseaseXiomara A Perez, Tanuja Bordia, J Michael McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 8, 2012
Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbensXiomara A Perez, Jason Ly, J Michael McIntosh, et al.
Molecular Pharmacology|April 6, 2007
Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatumTanuja Bordia, Sharon R Grady, J Michael McIntosh, et al.
Channels (Austin, Tex.)|October 14, 2008
Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applicationsBaldomero M Olivera, Maryka Quik, Michelle Vincler, et al.
Pharmacology Research & Perspectives|February 19, 2015
Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawalXiomara A Perez, Taline V Khroyan, J Michael McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2012
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatumTanuja Bordia, Maya Hrachova, Matthew Chin, et al.
Neurobiology of Disease|February 28, 2016
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasTanuja Bordia, Xiomara A Perez, Jaime Heiss, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2002
Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damageJennifer M Kulak, John L Musachio, J Michael McIntosh, et al.
Neuropharmacology|January 15, 2011
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian ratsLuping Z Huang, Carla Campos, Jason Ly, et al.
Journal of Neurochemistry|March 3, 2009
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeysLuping Z Huang, Neeraja Parameswaran, Tanuja Bordia, et al.
Pageof 8